OSE — Ose Immunotherapeutics SA Share Price
0.000.00%
Last trade - 00:00- €124.89m
- €154.27m
- €83.44m
- 66
- 88
- 39
- 75
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 15.06 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -66.68% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.96 | ||
| Price to Tang. Book | 6.31 | ||
| Price to Free Cashflow | 2.58 | ||
| Price to Sales | 1.5 | ||
| EV to EBITDA | 3.09 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 42.16% | ||
| Return on Equity | 86.29% | ||
| Operating Margin | 52.42% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 10.43 | 26.31 | 18.3 | 2.23 | 83.44 | 46.5 | 56.15 | 26.31% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | -72.3 | -23.17 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
OSE Immunotherapeutics SA, formerly Orphan Synergy Europe Pharma SA, is a France-based company, engaged in clinical stage biotechnological sector. It develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The Company's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. It provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.
Directors
- Dominique Costantini CHM (66)
- Maryvonne Hiance VCH (72)
- Anne-Laure Autret-Cornet CFO
- Nicolas Poirier CSO (39)
- Laurence De Schoulepnikoff OTH
- Jean-Pascal Conduzorgues MGB
- Sophie Brouard IND (50)
- Jean-Patrick Demonsang IND (68)
- Brigitte Dreno IND (68)
- Didier Hoch IND (65)
- Gerard Tobelem IND (73)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 3rd, 2004
- Public Since
- March 30th, 2015
- No. of Employees
- 52
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Euronext - Paris
- Shares in Issue
- 21,833,281
- Address
- 22, boulevard Benoni Goullin, NANTES, 44200
- Web
- https://ose-immuno.com/
- Phone
- +33 228291010
- Auditors
- Ernst & Young et Autres
Upcoming Events for OSE
Half Year 2025 OSE Immunotherapeutics SA Earnings Release
Similar to OSE
Abionyx Pharma SA
Euronext - Paris
Abivax SA
Euronext - Paris
Adocia SA
Euronext - Paris
Biophytis SA
Euronext - Paris
Cellectis SA
Euronext - Paris
FAQ
What is the Ose Immunotherapeutics SA share price?
As of Today at 04:29 UTC, shares in Ose Immunotherapeutics SA are trading at €5.72. This share price information is delayed by 15 minutes.
How has the Ose Immunotherapeutics SA share price performed this year?
Shares in Ose Immunotherapeutics SA last closed at €5.72 and the price had moved by +2.14% over the past 365 days. In terms of relative price strength the Ose Immunotherapeutics SA share price has underperformed the FTSE Global All Cap Index by -0.41% over the past year.
What are the analyst and broker recommendations for Ose Immunotherapeutics SA?
The overall consensus recommendation for Ose Immunotherapeutics SA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Ose Immunotherapeutics SA dividend yield?
Ose Immunotherapeutics SA does not currently pay a dividend.
Does Ose Immunotherapeutics SA pay a dividend?
Ose Immunotherapeutics SA does not currently pay a dividend.
When does Ose Immunotherapeutics SA next pay dividends?
Ose Immunotherapeutics SA does not currently pay a dividend.
How do I buy Ose Immunotherapeutics SA shares?
To buy shares in Ose Immunotherapeutics SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Ose Immunotherapeutics SA?
As of the previous close price of €5.72, shares in Ose Immunotherapeutics SA had a market capitalisation of €124.89m.
Where are Ose Immunotherapeutics SA shares listed?
Here are the trading details for Ose Immunotherapeutics SA:
- Country of listing: France
- Exchange: PAR
- Ticker Symbol: OSE
What kind of share is Ose Immunotherapeutics SA?
Based on an overall assessment of its quality, value and momentum Ose Immunotherapeutics SA is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Ose Immunotherapeutics SA share price forecast for 2025?
The analyst consensus target price for shares in Ose Immunotherapeutics SA is €16.50. That is 188.46% above the last closing price of €5.72.
Analysts covering Ose Immunotherapeutics SA currently have a consensus Earnings Per Share (EPS) forecast of €0.41 for the next financial year.
Find out moreWhat is the trend in the Ose Immunotherapeutics SA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ose Immunotherapeutics SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -42.99%.
As of the last closing price of €5.72, shares in Ose Immunotherapeutics SA were trading -22.93% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Ose Immunotherapeutics SA PE Ratio?
The Ose Immunotherapeutics SA PE ratio based on its reported earnings over the past 12 months is 15.06. The shares last closed at €5.72.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Ose Immunotherapeutics SA?
Ose Immunotherapeutics SA's management team is headed by:
- Dominique Costantini - CHM
- Maryvonne Hiance - VCH
- Anne-Laure Autret-Cornet - CFO
- Nicolas Poirier - CSO
- Laurence De Schoulepnikoff - OTH
- Jean-Pascal Conduzorgues - MGB
- Sophie Brouard - IND
- Jean-Patrick Demonsang - IND
- Brigitte Dreno - IND
- Didier Hoch - IND
- Gerard Tobelem - IND